An­gion's or­gan dam­age drug strikes out again, this time in high-risk kid­ney trans­plant pa­tients

Af­ter flop­ping a test in Covid-19 ear­li­er this year, An­gion’s lead or­gan dam­age drug has now hit the skids again in kid­ney trans­plant pa­tients.

An­gion and part­ner Vi­for Phar­ma’s ANG-3777 failed to beat out place­bo in terms of im­prov­ing eGFR, a mea­sure of kid­ney func­tion, in pa­tients who had re­ceived a de­ceased donor kid­ney trans­plant and were at high risk of de­vel­op­ing what is known as de­layed graft func­tion, ac­cord­ing to Phase III re­sults re­leased Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA